West Pharmaceutical Services, Inc. announced that its Board has approved the payment of a third-quarter 2013 cash dividend of $0.19 per share. The dividend will be paid on August 7, 2013 to shareholders of record on July 24, 2013.

West Pharmaceutical Services, Inc. Presents at UBS Global Healthcare Conference, May-22-2013 11:00 AM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Donald E. Morel, Chairman and Chief Executive Officer, William J. Federici, Chief Financial Officer and Vice President.

West Pharmaceutical Services, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported net sales of $339.4 million compared to $316.3 million a year ago. Consolidated sales grew by 7.3%, or $23.1 million, compared to the first quarter of 2012, driven by increased sales of Packaging System's high-value packaging components, which were 11.2% higher, and Delivery System's proprietary products. Operating profit was $43.3 million compared to $41.7 million a year ago. Income before income taxes was $39.1 million compared to $37.8 million a year ago. Net income was $31.7 million or $0.90 assuming diluted per share compared to $29.2 million or $0.81 assuming diluted per share a year ago. The company reported adjusted non-GAAP operating profit of $43.3 million and adjusted non-GAAP net income of $30.6 million or $0.87 per diluted share compared to adjusted non-GAAP operating profit of $42.3 million and adjusted non-GAAP net income of $29.9 million or $0.83 per diluted share for the same period a year ago. Operating cash flow was $18.9 million compared to $13.8 million a year ago. Capital expenditures were $61.7 million compared to $32.4 million a year ago. The effective tax rate on adjusted pre-tax profit declined 0.2 percentage points from the prior-year period, to 25.1% for 2013. For the year 2013, the company's expected annual effective tax rate is 25.9% on adjusted pre-tax earnings, compared to the 27.3% actual annual effective tax rate for 2012. The company expects consolidated net sales of $1,360 million to $1,400 million, consolidated gross profit margin of 31.2% to 31.8%, full-year diluted EPS of $3.08 to $3.23 and full-year adjusted diluted of $3.05 to $3.20 as compared to net sales of $1,360 million to $1,400 million, consolidated gross profit margin of 30.7% to 31.3%, full-year diluted EPS of $3.00 to $3.20 and full-year adjusted diluted of $2.97 to $3.17 as previously reported. The company expects to spend approximately $125 million to $150 million in capital in 2013.